Applied Molecular Transport Appoints Douglas Rich as Chief Technical Officer
19 Enero 2021 - 7:00AM
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a
clinical-stage biopharmaceutical company, today announced that it
has appointed Douglas Rich as Chief Technical Officer. In his new
role, Douglas will assume leadership responsibilities for all
process development, manufacturing, CMC and formulation activities,
including quality and supply chain responsibilities. He will become
a member of the AMT Executive Team, reporting to chief executive
officer and co-founder of AMT, Tahir Mahmood, Ph.D.
“We continue to recognize the criticality of
furthering our internal GMP manufacturing and formulation
development for the company’s long-term success,” stated Tahir
Mahmood, Ph.D. “Doug’s significant experience in technical
operations and quality, and track record of building and leading
high caliber teams, will serve as foundational components of our
growth strategy. Last month, we initiated our second and third
Phase 2 trials for oral AMT-101, FILLMORE for patients with
pouchitis and CASTRO with oral AMT-101 in combination with approved
anti-TNFα therapy for patients with rheumatoid arthritis. With
continued progress in the clinic and across the business, I look
forward to Doug’s important contributions as we advance our
promising pipeline of novel, oral biologic medicines.”
With more than 26 years of experience in the
biopharma industry, Mr. Rich brings deep operations and quality
experience across the entire product lifecycle. He has served in
leadership roles responsible for the development and
commercialization of both biopharmaceuticals and small molecules.
Mr. Rich most recently served as Senior Vice President, Operations
at UNITY Biotechnology where he led Technical Operations, Quality,
Supply Chain, and Portfolio/Project/Alliance Management. Prior to
UNITY, he was Senior Vice President, Operations at Kythera
Biopharmaceuticals, acquired by Allergan plc. Prior to Kythera, he
was Vice President, Quality at Boehringer-Ingelheim where he worked
in both the Biopharmaceutical and Prescription Medicine Business
Units. Earlier in his career, Mr. Rich also spent over 18 years at
Amgen, in various roles within Operations including Global
Operations Strategy, Manufacturing, Quality Control, and Site
Quality Head.
“I am extremely excited about joining the
company at such an important time,” said Douglas Rich, chief
technical officer of AMT. “It is critical to continue to build on
the vision propelled by our technology platform and internal GMP
manufacturing, product formulation and other technical capabilities
to expand and advance our deep pipeline of promising oral biologic
products.”
About Applied Molecular Transport Inc.
Applied Molecular Transport Inc. is a
clinical-stage biopharmaceutical company leveraging its proprietary
technology platform to design and develop a pipeline of novel oral
biologic product candidates to treat autoimmune, inflammatory,
metabolic, and other diseases. AMT’s proprietary technology
platform allows it to exploit existing natural cellular trafficking
pathways to facilitate the active transport of diverse therapeutic
modalities across the intestinal epithelium (IE) barrier. Active
transport is an efficient mechanism that uses the cell’s own
machinery to transport materials across the IE barrier. AMT
believes that its ability to exploit this mechanism is a key
differentiator of its approach. AMT is developing additional oral
biologic product candidates in patient-friendly oral forms that are
designed to either target local gastrointestinal tissue or enter
systemic circulation to precisely address the relevant biology of a
disease.
AMT’s headquarters, internal GMP manufacturing
and lab facilities are located in South San Francisco, CA. For
additional information on AMT, please visit www.appliedmt.com.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
Forward-looking statements generally relate to future events or
AMT’s future plans, strategy and performance. Such statements
include, but are not limited to, the potential of, and expectations
regarding AMT’s technology platform and AMT-101, statements
regarding AMT’s Phase 2 clinical trials for AMT-101 including the
timing of such trials and the dosing related to such trials, AMT’s
ability to leverage its technology to expand its pipeline and Mr.
Doug Rich’s potential contributions to AMT. Such statements are
subject to numerous important factors, risks and uncertainties that
may cause actual events or results to differ materially, including
those more fully described under the section entitled “Risk
Factors” in documents the company files from time to time with the
Securities and Exchange Commission. These forward-looking
statements are made as of the date of this press release, and AMT
assumes no obligation to update the forward-looking statements, or
to update the reasons why actual results could differ from those
projected in the forward-looking statements, except as required by
law.
Investor Relations Contact:Andrew ChangHead,
Investor Relations & Corporate
Communicationsachang@appliedmt.com
Media Contacts:Alexandra SantosWheelhouse Life
Science Advisorsasantos@wheelhouselsa.com
Aljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Applied Molecular Transp... (NASDAQ:AMTI)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Applied Molecular Transp... (NASDAQ:AMTI)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024